We have constructed stable virus-like particles displaying the HIV-1 Gag(p17) protein as an N-terminal fusion with an engineered protein domain from the Geobacillus stearothermophilus pyruvate dehydrogenase subunit E2. Mice immunized with the Gag(p17)-E2 60-mer scaffold particles mounted a strong and sustained antibody response. Antibodies directed to Gag(p17) were boosted significantly with additional immunizations, while anti-E2 responses reached a plateau. The isotype of the induced antibodies was biased towards IgG1, and the E2-primed CD4+ T cells did not secrete IFNγ. Using transgenic mouse model systems, we demonstrated that CD8+ T cells primed with E2 particles were able to exert lytic activity and produce IFNγ. These results show that the E2 scaffold represents a powerful vaccine delivery system for whole antigenic proteins or polyepitope engineered proteins, evoking antibody production and antigen specific CTL activity even in the absence of IFNγ-producing CD4+ T cells.
Introduction
After 25 years of HIV research and several failed vaccine trials (Buchbinder et al., 2008) , despite some evidence for modest vaccine protection in humans (Rerks-Ngarm et al., 2009) , new vaccine modalities are still needed to elicit the high-titer and durable immune responses. These responses include, but may not be limited to, cytotoxic T cells (CTL) directed to multiple viral proteins, strong T helper responses, and neutralizing antibodies (NAbs) that are effective against a broad range of primary HIV-1 isolates. Proof-ofprinciple experiments in nonhuman primate challenge models have been useful in understanding the role of antibodies in blocking infection, when they are present at sufficient titers in advance of exposure (Baba et al., 2000; Hessell et al., 2009; Mascola et al., 2000; Shibata et al., 1999) . Similarly, the presence of T cell responses is correlated with viral control, as shown by T cell depletion studies in nonhuman primates (Lifson et al., 2001; Schmitz et al., 2005) and protection from disease when strong T cell responses are induced by vaccination with recombinant viral vectors (Hansen et al., 2009; Santra et al., 2005) . Efforts have thus been focused on designing vaccines and delivery systems that can elicit strong, durable immunity that is directed against multiple viral antigens, to prevent ready escape. Current methods for eliciting T-cell responses for HIV, in particular, have presented limitations due to poor immunogenicity that is limited in seropositive individuals (O'Brien et al., 2009) . However, in the case of some vectors, such as adenovirus, strategies have been proposed to circumvent anti-vector immunity (Roberts et al., 2006) . Moreover, combining two or more vaccine modalities in "prime-boost" regimens can elicit stronger immune responses than either vaccine alone (Kibuuka et al., 2010; Koup et al., 2010; RerksNgarm et al., 2009) .
The inactivated HIV virion itself has long been considered as a vaccine candidate and this approach, especially for therapeutic vaccines, was championed by polio vaccine luminary Jonas Salk (Salk, 1987) . Protective efficacy with formalin-inactivated SIV in nonhuman primates was demonstrated (Johnson et al., 1992; Murphey-Corb et al., 1990) but the vaccine was complicated by the Virology 407 (2010) [296] [297] [298] [299] [300] [301] [302] [303] [304] [305] presence of host HLA, which was shown to be the mechanism for protection-unrelated to the SIV antigens (Arthur et al., 1995; Stott, 1991) . Recent advances in understanding of virus assembly have led to the development of methods that chemically and irreversibly inactivate whole virions and that maintain the receptor binding activity of Envelope (Arthur et al., 1998; Lifson et al., 2004) . The attractiveness of VLPs that can mimic the natural HIV virion without any risk of HIV infection led to the early development of recombinant Gag-Env particles produced in mammalian cells by recombinant vaccinia virus (Haffar et al., 1990 (Haffar et al., , 1991 (Haffar et al., , 1992 Luo et al., 2003) , or rhinovirus chimeras (Arnold et al., 1994; Lapelosa et al., 2010) , yeast (Tsunetsugu-Yokota et al., 2003) , or in other systems, reviewed in (Deml et al., 2005) . While clearly immunogenic in eliciting Gagspecific CTL (Paliard et al., 2000) and antibodies, including some neutralizing antibodies (Ding et al., 2002) , none of these approaches has elicited strong protective immunity. Explanations for low level immunogenicity may include dose, stochiometry of key immunogens such as Envelope (when present), or delivery or adjuvant systems employed to date.
We have previously designed and investigated a new delivery vehicle in which antigenic determinants are inserted on the surface of an icosahedral scaffold formed by the acyltransferase component (E2 protein) of the multienzyme pyruvate dehydrogenase complex (PDH) from Geobacillus stearothermophilus, and reported the ability of this scaffold to display peptides in a high immunogenic form Domingo et al., 2003) . The core C-terminal catalytic domain of E2 self-assembles into trimers, which in turn aggregate to generate a 60-chain core with icosahedral symmetry (Domingo et al., 2001; Henderson et al., 1979; Perham, 2000) . Moreover this 60-meric icosahedral structure can be regenerated with high efficiency from denaturing conditions in vitro, without the need of chaperonins (Allen and Perham, 1997; Lessard et al., 1998) . The robustness of this peptide based virus-like particle has rendered it an attractive macromolecular scaffold for presentation of exogenous molecules on its surface Domingo et al., 2001 Domingo et al., , 2003 and for molecular encapsulation in its cavity (Dalmau et al., 2008 (Dalmau et al., , 2009a . Efficient refolding of E2 to the 60-mer is also possible with foreign peptides replacing the natural peripheral domains, as N-terminal fusions to the core domain. Thus, a suitably engineered E2 core (E2DISP) can display 60 copies of heterologous peptides on the surface of a high molecular mass scaffold Domingo et al., 2001 Domingo et al., , 2003 . This property can be exploited for vaccine design. Here we further expanded the delivery properties of the E2 scaffold by displaying a whole protein at the surface of the scaffold, and analyzed the in vivo induction of B and T cell responses.
Results

Construction of E2 particles
We constructed OVA 257-264 E2 and OVA 323-339 E2 particles expressing the OVA peptides at the N-terminus of E2. We also constructed Gag(p17)-E2, and Gag(p17)-OVA 257-264 -E2 particles respectively expressing the HIV-1 Gag-p17 protein at the N-terminus of E2 or, in addition, the OVA 257-264 peptide between the E2 carrier protein and the HIV-1 Gag(p17) protein. Both the Gag(p17)-E2 and Gag(p17)-OVA 257-264 -E2 fusion proteins also assembled into 24 nm virus-like E2 particles expressing up to 60 copies of the HIV-1 Gag(p17) or Gag (p17)-OVA 257-264 antigens on their surface (see Fig. 1 ). Hybrid particles displaying equimolar amounts of pep23E2 and Gag(p17)-E2 particles which co-express a strong T helper epitope from HIV-1 reverse transcriptase were also generated ( Fig. 1 ) according to previously described methodologies . Correct folding of these particles was demonstrated by gel filtration chromatography to confirm size and electron microscopy analysis (data not shown).
Generation of Gag(p17) specific CTLs
To investigate the ability of Gag(p17)-E2 particles to elicit peptidespecific CTL responses in vivo, HHD (HLA-A2.1/H2-D b ) transgenic mice were immunized with double-display pep23E2/Gag(p17)-E2 particles and the generation of CTLs specific for the HLA-A2 restricted Gag(p17) epitope SLYNTVATL was examined. Since we previously reported that in the HHD mouse model the immunization with E2 particles co-expressing helper and cytotoxic T cell epitopes is a requirement for inducing a CTL response, we used the pep23E2/Gag (p17)-E2 particles co-expressing the pep23 helper epitope to ensure strong T cell help in these mice . Splenocytes were isolated from mice immunized twice and restimulated in vitro for 5 days with syngeneic LPS-induced blast cells pulsed with the same E2 particles used for immunization. Effector cell-mediated cytotoxic activities were tested in 51 Cr release assays towards RMA-S-HHD (Tap -, HLA-A2.1 + ) target cells loaded with the Gag(p17) SLYNTVATL synthetic peptide. As shown in Fig. 2A , specific cytotoxic activities were generated in splenocytes isolated from mice immunized (in the absence of adjuvants) with pep23E2/Gag (p17)-E2 particles. This response was similar in mice immunized in the presence of adjuvant (data not shown). In contrast, no cytotoxic activity was found in splenocytes isolated from mice immunized with E2 wt particles ( Fig. 2A) . Splenocytes isolated from unimmunized mice and restimulated in vitro with pep23E2/Gag (p17)-E2 particles-pulsed LPS-blasts did not exert cytotoxic activity (data not shown).
Induction of anti-Gag(p17) antibodies
We measured total IgG titers against Gag and E2 proteins in the sera of mice (three groups of three mice each) bled after one or two doses of Gag(p17)-E2, pep23E2/Gag(p17)-E2 or E2 wt particles, which were administered s.c. either in the presence or in the absence of adjuvants. The IgG antibodies against Gag were scarcely detectable after one dose but were strongly evident after two doses (Fig. 2B) . No differences were observed between groups of mice immunized with particles displaying Gag(p17) alone or hybrid particles displaying pep23E2/Gag(p17)-E2 particles (Fig. 2B ). Antibodies directed against E2 were detectable after one dose and boosted by the second dose (not shown). The high titer of antibodies persisted for 30 weeks (Fig. 2B ). IgG isotype was significantly biased in favor of IgG1 as compared to the response obtained in mice immunized with vaccinia Gag used as a control (Fig. 2C ). The antibody production was similar in the sera of mice immunized in the absence or in the presence of IFA or CpG adjuvants (Fig. 2C) . In separate experiments, we immunized C57BL6xBALB/c mice three times (weeks 0, 4, and 31) with Gag(p17)-E2 alone; E2-specific responses were not further enhanced by the third immunization, while the Gag-specific responses increased significantly with the third dose (data not shown).
We conclude that: 1) the HIV-1 Gag(p17) protein displayed on Gag (p17)-E2 particles is strongly immunogenic in the absence of adjuvant; 2) responses to Gag are primed by one dose and boosted with a second or third dose; 3) antibodies level persisted for many weeks, at least 27 weeks; 4) although responses to E2 increase with a boosting dose, this does not abrogate the boosting effect for Gag responses; and 5) co-expression on E2 of exogenous helper epitopes is not needed for antibody production in the immunized mice.
Role of CD4+ T cells in IgG1 induction
In order to analyze the role of CD4+ T cell help in the induction of an antibody response characterized by the IgG1 isotype, we assessed the production of IFNγ in CD4+ T cells isolated from C57BL/6xBALB/c (MHC H-2 bd ) F1 mice immunized with Gag(p17)-E2, and stimulated with overlapping peptides (15 amino acid residue length) encompassing the Gag(p17) sequence. The CD4+ T cells from mice immunized with one or two doses of Gag(p17)-E2 particles did not produce IFNγ upon restimulation with 15-mer Gag peptides (data not shown). This result may be consistent with the lack of T helper epitopes restricted by mouse MHC H-2 bd in the Gag(p17) sequence, as these epitopes are not reported in the NIH database. Thus, in order to assess the role of CD4+ T cell help in the induction of antibodies with the IgG1 isotype, we chose to study the response to a well-established epitope such as the MHC H-2 b -restricted chicken ovalbumin 323-339 (OVA 323-339 ) epitope. For this study we used OVA 323-339 E2 particles and the OT-II mice which have CD4+ T cells expressing a transgenic TCR specific for the OVA 323-339 epitope. According to established protocols (Parish et al., 2009) immunization with E2 wt particles was also performed. After 3 days, isolated splenocytes were evaluated for OT-II proliferation as assayed by CFSE dilution, and the results illustrated in Fig. 3A -B show a strong proliferative response of OT-II CD4+ T cells in OVA 323-339 E2 treated mice as compared to the proliferative response observed in mice which received soluble OVA plus poly(I:C). We also measured IFNγ production by intracellular staining of splenocytes. As illustrated in Fig. 3C -D, CD4+ OT-II cells did not produce IFNγ upon restimulation with the OVA 323-339 synthetic peptide. Nonspecific stimulation with PMA plus ionomycin gave rise to high levels of IFNγ (data not shown).
Priming with E2 particles induces antigen specific CD8+ T cells able to produce IFNγ
We also performed a study using the OT-I model characterized by CD8+ T cells expressing a transgenic TCR able to recognize the CTL epitope SIINFEKL from chicken ovalbumin residues 257-264 (OVA [257] [258] [259] [260] [261] [262] [263] [264] ). In this case we did not use E2 particles co-expressing the helper epitope pep23 because we previously reported (Del Pozzo et al., 2010; Mascolo et al., 2007 ) that co-expression of a helper epitope in the immunizing particles is not necessary to obtain a CTL response specific towards the OVA 257-264 peptide in C57BL/6 wild type mice. Thus, after the adoptive transfer of CSFE-labeled OT-I/CD8+ T cells, C57BL/6 recipient mice were immunized with E2 particles expressing the OVA 257-264 peptide. After 3 days splenocytes were isolated from the immunized mice and respectively evaluated for OT-I proliferation and IFNγ production. As illustrated in Fig. 4A -B, a specific proliferation, as assessed by CSFE dilution, was observed on CD8+ T cells isolated from mice immunized with OVA 257-264 E2 particles. In contrast to OT-II CD4+ T cells, the OT-I CD8+ T cells were able to produce IFNγ upon restimulation with the specific OVA 257-264 synthetic peptide (Fig. 4C-D) .
Induction of cytotoxic T cells by Gag(p17)-OVA 257-264 -E2 particles
We thus constructed a fusion protein expressing the OVA 257-264 CTL epitope between the E2 carrier and the Gag(p17) protein, and assessed the production of OVA specific CTL in C57BL/6 wild type mice. Aim of this analysis was to demonstrate the ability of E2 particles to be processed and to cross-present the OVA 257-264 CTL epitope even if it was located in an internal position in comparison with E2 particles expressing the OVA [257] [258] [259] [260] [261] [262] [263] [264] OVA 257-264 -E2 or OVA 257-264 -E2 particles. Furthermore, we also visualized, by intracellular staining, the production of IFNγ by CD8+ T cells isolated from the immunized mice and restimulated with the OVA 257-264 synthetic peptide (Fig. 5C ).
Discussion
We previously described the immunogenicity of small epitopes (9-15 aa) displayed on the E2 scaffold Domingo et al., 2003) . However, larger protein antigens may be more useful, as they contain multiple T cell epitopes as well as antibody determinants in their native context. Each E2 chain in the G. stearothermophilus PDH complex naturally displays, at the N-terminus of the acyltransferase core domain, 187 amino acid residues in the form of the two folded protein domains (lipoyl and peripheral subunit binding) and two flexible linkers. Moreover, the E2 system is naturally designed to present up to 60 copies of the E1 (~150 kDa) or E3 (~100 kDa) enzymes noncovalently attached on its surface. Thus, in theory, it is possible that large polypeptides can be attached to the E2 scaffold, which is formed by the acetyltransferase core domain.
In this context, we have expressed on E2 the HIV-1 Gag(p17) protein. Expression of this protein allowed the correct folding of the 60-mer scaffold. Moreover, Gag(p17) was expressed in a native form being recognized by a monoclonal antibody specific for a conformational epitope of the Gag(p17) protein (De Berardinis and Haigwood, 2004) . Here we show the ability of Gag(p17) to induce in vivo a sustained humoral immune response. In fact, high titers of antibodies were detected after immunization in the absence of added adjuvants and the specific antibodies were still present in mice sera 30 weeks after the immunizations. The presence of an exogenous T cell help codisplayed by the E2 particles was not necessary for mice to mount a sustained antibody response. This result is in agreement with previously reported data on antibody production by immunizing with E2 particles not co-expressing an exogenous helper peptide (Domingo et al., 2001 . However, we cannot exclude that the primed mice may recognize MHC H2 bd restricted T helper epitope/s present in the E2 scaffold. The analysis of IgG subclasses raised in mice sera indicates a bias towards IgG1 response, suggesting that a Th2-type response (Reiner and Locksley, 1995) is preferentially induced by E2 antigen delivery. However, we do not have a direct evidence for the role of E2-mediated T cell help in the induction of the anti-Gag IgG1 response. Immune responses in humans against most infections are of mixed pattern or balanced between Th1 and Th2. The balance needed between the induction of an effective antibody response versus a T cell response in protecting against live infection, is not well understood. However, we can hypothesize that in order to combat specific pathogens, it may be advantageous to preferentially induce a Th1 or Th2-type of response. Moreover, it is known that addition of a different kind of adjuvant may shift the immune response towards alternative pathways. In this context, it is important to assess which type of response is induced by a particular delivery vehicle in order to use it for eliciting a preferred pattern of cytokines response. Here we have analyzed the CD4+ T cell response induced by E2 delivery using the OT-II mouse model. We observed that the proliferating OT-II CD4+ T cells, primed with E2 particles carrying the OVA 323-339 peptide, did not produce IFNγ. Future work will be addressed to identify the cytokines produced by the CD4+ T cells upon priming via E2 antigen delivery.
We also studied the CD8+ T cell response in HHD transgenic mice, in the OT-I model and in C57BL/6 mice. In order to study the response in HHD mice we used E2 particles co-displaying the helper peptide pep23 because we previously observed that a CTL response can be induced in these mice only by E2 particles co-displaying an exogenous strong helper epitope . On the other hand, according to previous findings in another system (Del Pozzo et al., 2010; Mascolo et al., 2007) we found that that co-expression of the pep23 helper epitope was not necessary to induce a CD8+ T cell response against the OVA 257-264 antigenic peptide SIINKFEL in OT-I and in C57BL/6 wild type mice. The data obtained, using the OT-I model system, show the production of IFNγ by antigen specific CD8+ T cells. These results are in contrast to data obtained with CD4+ T cells in the OT-II model. Moreover, in wild type C57BL/6 mice immunized with E2 particles carrying the OVA 257-264 peptide as a fusion with the Gag(p17) we also induced antigen-specific CD8+ cytotoxic T cells able to produce IFNγ. CTL specific for the HLA-A2 restricted Gag(p17) epitope SLYNTVATL were also induced in HHD transgenic mice immunized with pep23E2/Gag(p17)-E2 particles. It should be emphasized that in both of these latter constructs the CTL epitopes were located in an internal position, requiring processing for class I presentation. This suggests that E2 delivery may be employed to obtain response towards whole immunogenic proteins or to display engineered constructs encompassing multiple epitopes. In this context we have previously observed that E2 particles can reach both the MHC class I and class II compartments . Vaccines designed to limit or prevent HIV infection are generally thought to require broad sustained humoral and cellular immune responses to be effective (Fauci et al., 2008) . These types of responses have been difficult to elicit with existing approaches, even by combining modalities. Thus, both novel immunogens and more effective antigen presentation strategies are needed to complement the existing array of options or to be used in prime-boosting immunization strategies (Barnett et al., 1997; Doria-Rose et al., 2003; Law et al., 2007) . From these data we can conclude that the Gag (p17) HIV-1 protein is effectively presented to the immune system by the E2 scaffold. In immunized mice this scaffold elicits, not only the production of a sustained humoral response, but also the induction of cytotoxic T cells. The ability of virus-like particles similar in size to the E2 scaffold to elicit both types of immunity represents an advantage over recombinant proteins, which primarily target antibody generation and viral vectors that are most effective in eliciting cell mediated responses. In theory, multiple HIV antigens and immune effectors/ adjuvants can be presented on the same scaffold, limited only by steric constraints and solubility. In this context, the E2 antigen delivery system, which affords simplicity and safety along with the capability of inducing sustained humoral and cellular antigen-specific immune responses, represents a promising new tool that can be combined with other approaches to advance the field of vaccinology.
Materials and methods
Construction of E2 vectors
The OVA 257-264 -E2, OVA 323-339 -E2, Gag(p17)-E2 and Gag(p17)-OVA 257-264 -E2 vectors were constructed from the previously described pETE2DISP Domingo et al., 2001 Domingo et al., , 2003 , to allow the expression, as N-terminal fusion to the E2 core scaffold, of the ovalbumin (OVA) peptides 257-264 and 323-339 (OVA 257-264 and OVA 323-339 ), the HIV-1 Gag(p17) protein and the OVA 257-264 peptide fused to the HIV-1 Gag(p17) protein.
Oligonucleotide sequences encoding the OVA peptides sequence SIINFEKL and ISQAVHAAHAEINEAGR with the protruding ends for NcoI and XmaI restriction enzymes (New England Biolabs, MA, USA) were purchased from Primm srl (Naples, Italy). OVA oligonucleotide sequences were inserted into the NcoI and XmaI digested pETE2DISP by ligation with T4 DNA ligase (New England Biolabs) to generate OVA 257-264 -E2 and OVA 323-339 -E2 vectors.
The segment of DNA encoding the HIV-1 Gag(p17) protein was amplified by polymerase chain reaction (PCR) from pNL4-3Gag vector (gift of Dr. Ned Landau) using the two oligonucleotides SEQ3: 5′ CATGCCATGGCCGGTGCGA3′ and SEQ4: 5′CATGCCATGGCG-TAATTTTGGCTGACC3′. Gag(p17) PCR product digested with NcoI and XmaI restriction enzymes was ligated into the previously digested pETE2DISP to generate Gag(p17)-E2 vector. Oligonucleotide sequences SEQ3 and SEQ5: 5′CATGCCCGGGCGTAATTTTGGCTGACC3′ were employed to amplify Gag(p17) cDNA from Gag(p17)-E2 vector and to introduce NcoI restriction sites at the 5′ and 3′ ends. The Gag (p17) amplified cDNA was thus digested and inserted into the NcoI digested OVA 257-264 -E2 vector by ligation with T4 DNA ligase to generate Gag(p17)-OVA 257-264 -E2 vector.
The BL21 (DE3) E. coli bacteria cells containing circular plasmids were selected on LB medium plates containing ampicillin (Sigma, Milan, Italy) and successful construction of the plasmids was confirmed by DNA sequence analysis (Primm srl.). The construction of pep23E2 vector, expressing the KDSWTVNDIQKLVGK T helper epitope from reverse transcriptase of HIV-1 was described previously .
Expression and purification of E2 proteins
One liter of LB medium containing 100 μg/ml ampicillin and 30 μg/ml kanamycin (Sigma) was inoculated with 10 ml of an overnight culture of E. coli BL21 (DE3) co-transformed with OVA 257-264 -E2, OVA 323-339 -E2, Gag(p17)-E2 or Gag(p17)-OVA 257-264 -E2 and with pGroEL/ES vectors Domingo et al., 2001 Domingo et al., , 2003 . Cultures were grown at 37°C until an optical density of 0.6 (600 nm) was obtained. The cells were then heat-induced overnight at 30°C with 2 mM Isopropyl β-D-1-thiogalactopyranoside (IPTG). The Gag(p17)-E2 cell pellet was resuspended in buffer A: 30 mM potassium phosphate pH 6.4, 1 mM phenylmethanesulphonylfluoride (PMSF, Sigma) containing 0.1 mg/ml lysozyme (Sigma), and lysed by sonication. The supernatant containing Gag(p17)-E2 protein was recovered by centrifugation (10,000 × g for 1 h). The proteins that were precipitated between 35% and 40% saturation of ammonium sulphate were redissolved in buffer A, dialysed against two changes of the same buffer and applied on a Pharmacia Mono S HR10/10 HP cation exchange column previously equilibrated with buffer (20 mM Tris-HCl pH 8.5, 10 mM EDTA, 1 mM PMSF). The Gag (p17)-E2 protein was eluted with a linear gradient of 0-1 M NaCl in buffer A at a flow rate of 1 ml/min over 200 ml. The Gag(p17)-OVA 257-264 -E2 cell pellet was resuspended in 20 mM potassium phosphate pH 7.4, 1 mM PMSF (buffer B) containing 0.1 mg/ml lysozyme and lysed by sonication. The supernatant containing Gag (p17)-OVA 257-264 -E2 protein recovered by centrifugation (10,000 × g for 1 h) was applied on a Biorad UNOS12 cation exchange column previously equilibrated with buffer B. The Gag(p17)-OVA 257-264 -E2 protein was eluted with a linear gradient of 0-1 M NaCl in buffer B at a flow rate of 1 ml/min over 200 ml. The fractions containing the E2 proteins were concentrated using a Centriprep30 (Millipore, MA) and loaded into a Pharmacia Superose-6 gel filtration column previously equilibrated with 50 mM potassium phosphate. The concentration of all the E2 constructs was determined by Coomassie dye binding method (Bradford assay). OVA 257-264 -E2, OVA 323-339 -E2 and pep23E2 complexes were purified using the same condition of E2 wild type (E2 wt) complex purification that was previously described Domingo et al., 2001 Domingo et al., , 2003 . The hybrid assembly, pep23E2/Gag(p17)-E2, displaying both Gag(p17) and pep23, was generated by in vitro denaturation and refolding of mixtures of E2pep23 and Gag(p17)-E2 according to previously described protocol . Briefly, equimolar quantities of purified pep23E2 and Gag(p17)-E2 were mixed and dialyzed against buffer B containing 5 M GuHCl and 1 mM DTT, followed by dialysis against buffer B without 5 M GuHCl. Reconstitution of soluble E2 60-mer core structures in high yield (N90%) was confirmed by gel filtration and electron microscopy as previously described . The purified proteins samples were stored at −80°C.
Mice
Female C57BL/6xBALB/c F1 hybrid mice (Jackson Laboratory, Bar Harbor, ME, USA) were housed at the University of Washington, USA. HHD transgenic mice (Pascolo et al., 1997 ) expressing a chimeric HLA-A2.1/H-2-D b MHC class I molecule on a C57BL/6 genetic background, were kindly provided by Dr. F. A. Lemonnier (Pasteur Institute, Paris, France). C57BL/6 mice, C57BL/6 OT-II Thy1.1+ or OT-I transgenic mice were purchased from Charles River Laboratory (Lecco, Italy).
Mice were maintained at the animal facility of CNR, Naples, Italy. All animals were housed in specific pathogen free condition in accordance with the standards outlined by the National Institutes of Health Guide for the Care and Use of Laboratory animals. All experiments with mice were performed in accordance with European Union Laws and guidelines, and were approved by our institutional review board. The animal procedures (i.e. immunization, sacrifice) were performed according to rules approved by the ethical committee. In all case, 8-12 weeks old age-matched male mice were used for comparative studies.
Peptides
Overlapping 15-mer peptides encompassing the HIV Gag(p17) sequence (HIV-1 Con B Gag(p17) 15-mer) were obtained through the AIDS Research and Reference Reagent Program, Division of AIDS (NIAID, NIH, USA). The OVA 257-264 and OVA 323-339 peptides from chicken ovalbumin were purchased from Primm srl.
Antibody response and ELISA assay C57BL/6xBALB/c F1 hybrid mice were immunized subcutaneously (s.c.) with 100 μg of one of the following constructs: E2wt, Gag(p17)-E2, pep23E2/Gag(p17)-E2. Proteins were administered alone, or in combination with IFA (Sigma) or CpG-ODN (Cell Sciences, MA). Plaque forming units (PFU; 10 7 ) of recombinant vaccinia virus expressing HIV Gag (rVV-Gag) in 1× PBS were delivered intraperitoneally. Mice were immunized at weeks 0 and 4 and bled by retroorbital bleed 2 weeks after each immunization and after 30 weeks from the first immunization. Sera were collected from each mouse and analyzed by ELISA.
Briefly, 2 μg/ml p55 Gag (Chiron, Emeryville, CA) or E2 protein was diluted in 1× carbonate/bicarbonate buffer (Sigma) and coated onto 96-well plates (MaxiSorp TM , NUNC, NY) overnight at 4°C. Plates were blocked in Blotto (1× PBS/5% dry milk/1% normal goat sera) for 1 h at room temperature then washed five times and incubated for 5 min in Wash Buffer (1× PBS/0.1% Triton X-100). Three-fold serial dilutions of sera were performed with Disruption Buffer (1× PBS/5% FBS/2% BSA/ 1% Triton X-100) and incubated in plates for 1 h at room temperature. After washing, biotin-conjugated goat anti-mouse total IgG (1:1200) was diluted in Disruption Buffer and applied at 100 μl/well. After washing, a 1:800 dilution of ExtrAvidin-conjugated horse-radish peroxidase (HRP, Sigma) was added. For isotype-specific ELISAs, HRP-conjugated goat anti-mouse IgG1 (1:4000, Southern Biotech, Birmingham, AL), IgG2a (1:4000, Southern Biotech) were used, diluted in Disruption Buffer. After a final wash, plates were developed with 100 μl/well TMB liquid substrate (Sigma). Reactions were stopped with 1 N H 2 SO 4 (Fisher). Plates were read on a Molecular Device luminometer at A450-650 using SoftMax pro (Sunnyvale, CA, USA). The endpoint titer was calculated as the lowest positive value for each sample that was three-times the average background of naïve mouse sera included on each plate.
Adoptive transfer and in vivo proliferation assay CD4+ or CD8+ OVA-specific T cells were obtained from spleen of OT-II or OT-I mice by negative selection using the CD4+ and CD8+ T cell isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany). Enrichment for T cells was confirmed by flow cytometry and was typically 95-99% pure. The cells were labeled with 5 μM of Carboxyfluorescein Succinimidyl ester (CFSE, Sigma) in PBS for 10 min at 37°C, washed two times with PBS/0.1% BSA and twice with PBS.
CFSE (3 × 10 6 ) labeled OT-I CD8+ or OT-II CD4+ T cells were injected i.v. into C57BL/6 recipients. Twenty-four hours later, mice were immunized subcutaneously (s.c.) with 100 μg of each of the following constructs: OVA 257-264 -E2, OVA 323-339 -E2, E2wt or PBS. 5 C57BL/6 mice received 500 μg soluble ovalbumin protein plus 50 μg of poly(I:C) in PBS intra peritoneum. After 3 days, mice were sacrificed and cell suspensions of spleen were isolated and stained with PE conjugated anti-Vα2 and PE-Cy5-conjugated anti-CD8 or PE-Cy7-conjugated anti CD4 mAbs (BD Pharmingen, Milan, Italy). The CFSE fluorescence intensity was then evaluated by multicolor flow cytometry analysis using a FACS Canto cytometer (Becton Dickinson, CA, USA).
Intracellular staining
The analysis was performed on 3 × 10 6 splenocytes cultured with 10 μg/ml of synthetic peptides or OVA 323-339 ) for 5 h in presence of brefeldin A (Sigma) (10 mg/ml) in a U-bottom 96 well plate. Cells were cultured in absence of peptide (negative control) or with 30 ng/ml of Phorbol 12-myristate 13-acetate (PMA), 1 μg/ml of ionomycin (Sigma) as positive control. The cells were washed and stained with PE-Cy5 anti-CD8 or PE-Cy7 anti-CD4 mAb on ice for 30 min The cells were treated with Leucoperm TM kit (AbD Serotec, Kidlington, UK) at room temperature for 30 min, stained with PE conjugated anti-INFγ mAb (eBioscience, Hatfield, UK) according to manufacture instructions and analyzed by a FACS Canto cytometer (Becton Dickinson).
Cytotoxicity tests
Cytotoxic activity was assayed in HHD transgenic mice or C57BL/6 mice.
HHD transgenic mice were immunized at days 0 and 14 by injecting s.c. at the base of the tail 140 μg of double displaying pep23E2/Gag(p17)-E2 particles in the absence of adjuvants. A control group of mice received the same amount of E2 wild type particles. After 7 days mice were sacrificed and isolated splenocytes (5 × 10 6 )
were co-cultured with antigen-pulsed γ-irradiated (10,000 rad) lipopolysaccaride-blasts (LPS-blasts) (2.5 × 10 6 ) produced from syngeneic unimmunized animals. LPS-blast cells consisted of splenocytes that have been cultured in 25 μg/ml of LPS in RPMI-1640, supplemented with 10% FCS, 5 × 10 −5 M 2-ME, 1 mM glutamine, 1 mM sodium pyruvate, and 7 μg/ml dextran sulphate for 3 days and pulsed for 3 h with 50 μg/ml of the same E2 preparations used for the immunization procedure. After 5 days of co-culture, effector cells were harvested and assayed for cytotoxic activity by the standard 51 Cr release assay, using as target RMA-S HHD cells prepulsed or not with 10 μg/ml synthetic Gag peptide SLYNTVATL. The percentage of specific lysis was calculated as described . C57BL/6 mice were immunized twice at days 0 and 14 with 100 μg of Gag(p17)-OVA 257-264 -E2 or OVA 257-264 -E2 particles both displaying 5 μg of OVA [257] [258] [259] [260] [261] [262] [263] [264] . A control group of mice received two administrations of E2 particles in the same conditions as above. All mice were sacrificed and analyzed on day 28. Splenocytes (4 × 10 6 cells/well) were stimulated in 24 well plates with LPS-blasts (2 × 10 6 ) from syngeneic unimmunized mice, which were prepulsed with OVA 257-264 (10 μg/ml) and γ-irradiated, in presence of interleukin 2 (IL-2) at 20 U/ml. As positive control, spleen cells from each mouse were stimulated in parallel cultures with irradiated BALB/c female spleen cells bearing the H-2 d alloantigen. After 7 days, the specific CTL activity of effector cell cultures was determined using the JAM assay (Matzinger, 1991) with EL4 cells (H-2 b ) prepulsed or not with 10 μg/ ml of OVA 257-264 peptide as target cells. The percentage of specific lysis was calculated as described (Matzinger, 1991) .
Pentamer staining
Splenocytes were isolated from C57BL/6 mice 14 days after the second immunization with Gag(p17)-OVA 257-264 -E2, OVA 257-264 -E2 or E2 particles and restimulated in vitro with syngeneic LPS-induced blast cells pulsed with specific OVA 257-264 peptide. After 7 days, the effector cells (1 × 10 6 cells/100 μl) were incubated with mouse anti-Fc receptor mAb (2.4G2 mAb, BD Pharmingen) in ice for 15 min to block Fc receptors and stained with PE-labeled SIINFEKL K b pentamer or PElabeled SSYSYSSL K b pentamer (ProImmune, Oxford, UK) in ice for 45 min. FITC-conjugated anti-CD8 mAb (ProImmune) was added for additional 15 min. The cells were washed, fixed using PBS solution with 30% methanol and 0.4% paraformaldehyde. A minimum of 50,000 live, CD8-positive, gated events were acquired and analyzed by flow cytometry on a FACS Canto (Becton Dickinson).
Statistical analysis
Statistical analyses were performed using the unpaired, two-tailed Student's t-test. Differences were considered statistically significant when P b 0.05.
